Combined Treatment for Non-Healing Wounds in Chronic Lower Extremity Arterial Disease: A Comparative Study

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tulip Medicine
3 trials monitored
See all monitored trials
Diabetes
5,101 trials monitored
See 233 trials at risk
Endovascular interventions, such as balloon angioplasty and stenting, are commonly used for PAD due to their proven safety and effectiveness. However, traditional treatments for chronic non-healing wounds are often insufficient. Advances in cell biotechnology, particularly fibroblast therapy, show promise for enhancing wound healing, as fibroblasts play a crucial role in tissue repair and inflammation. This study aims to develop, assess, and evaluate the safety of a combined treatment approach that incorporates fibroblast therapy with existing methods for managing chronic non-healing wounds in PAD patients.
Trial Details
NCT Number NCT06724276
Lead Sponsor Tulip Medicine
Collaborators: National Research Oncology and Transplantology Center, Kazakhstan
Conditions
(from sponsor)		 Obliterans, Arteriosclerosis, Peripheral Arterial Disease, Diabetic Foot
Related terms Arteriosclerosis Obliterans, Atherosclerosis, Diabetes Mellitus, Diabetic Foot, Peripheral Arterial Disease
Enrollment 116 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov